Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC with PTCy for Hematological Diseases
NCT05805605Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- May 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute undifferentiated leukemia (AML-M0) and 12 more, sponsored by Masonic Cancer Center. Primary endpoints: Acute Graft-Versus-Host Disease at 12 months and Chronic Graft-Versus-Host Disease at 12 months. Started May 2023; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute undifferentiated leukemia (AML-M0)prolymphocytic leukemia (PLL)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05805605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805605.